Article Contents ::

Details About Generic Salt ::  Telmisar

Main Medicine Class:: Antihypertensive, Angiotensin II antagonist   

(tell-mih-SAHR-tan)
Micardis
Tablets: 40 mg
Tablets: 80 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 20 to 80 mg/day; usual starting dose 40 mg/day.

 

 Interactions

Digoxin: May increase plasma levels of digoxin, that may increase toxicity.

Lithium: Plasma concentrations may be increased by telmisartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

EENT: Sinusitis; pharyngitis. GI: Diarrhea. RESPIRATORY: Upper respiratory tract infection. OTHER: Back pain.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimester). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hepatic function impairment: Use with caution.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature.
  • Do not remove tablets from their blisters or containers until immediately before administration.
  • Anticipate combination with a diuretic if target BP values are not reached.
  • Do not administer to patients with intravascular volume depletion until the condition has been corrected.
  • Administer with caution and under close medical supervision to patients with biliary obstructive disorders or hepatic insufficiency.
  • Do not administer to pregnant women.

 

 Assessment/Interventions

  • Obtain patient history and drug history including allergies.
  • Monitor patient for potential adverse effects and drug interactions.
  • Monitor BP and pulse. Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify health care provider.
  • Closely monitor patients on dialysis for orthostatic hypotension.
  • Monitor BP, especially patients on dialysis.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.
OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, dizziness, tachycardia, bradycardia

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that telmisartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better. Instruct patient not to increase or decrease the dosage.
  • Instruct family and patient in BP and pulse measurement skills. Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of use of this product prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning to become pregnant, or breastfeeding. Inform the patient of potential harm to the fetus.

 

Drugs Class ::

(tell-mih-SAHR-tan)
Micardis
Tablets: 40 mg
Tablets: 80 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 20 to 80 mg/day; usual starting dose 40 mg/day.

 

 Interactions

Digoxin: May increase plasma levels of digoxin, that may increase toxicity.

Lithium: Plasma concentrations may be increased by telmisartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

EENT: Sinusitis; pharyngitis. GI: Diarrhea. RESPIRATORY: Upper respiratory tract infection. OTHER: Back pain.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimester). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hepatic function impairment: Use with caution.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature.
  • Do not remove tablets from their blisters or containers until immediately before administration.
  • Anticipate combination with a diuretic if target BP values are not reached.
  • Do not administer to patients with intravascular volume depletion until the condition has been corrected.
  • Administer with caution and under close medical supervision to patients with biliary obstructive disorders or hepatic insufficiency.
  • Do not administer to pregnant women.

 

 Assessment/Interventions

  • Obtain patient history and drug history including allergies.
  • Monitor patient for potential adverse effects and drug interactions.
  • Monitor BP and pulse. Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify health care provider.
  • Closely monitor patients on dialysis for orthostatic hypotension.
  • Monitor BP, especially patients on dialysis.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.
OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, dizziness, tachycardia, bradycardia

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that telmisartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better. Instruct patient not to increase or decrease the dosage.
  • Instruct family and patient in BP and pulse measurement skills. Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of use of this product prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning to become pregnant, or breastfeeding. Inform the patient of potential harm to the fetus.

Indications for Drugs ::

(tell-mih-SAHR-tan)
Micardis
Tablets: 40 mg
Tablets: 80 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 20 to 80 mg/day; usual starting dose 40 mg/day.

 

 Interactions

Digoxin: May increase plasma levels of digoxin, that may increase toxicity.

Lithium: Plasma concentrations may be increased by telmisartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

EENT: Sinusitis; pharyngitis. GI: Diarrhea. RESPIRATORY: Upper respiratory tract infection. OTHER: Back pain.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimester). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hepatic function impairment: Use with caution.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature.
  • Do not remove tablets from their blisters or containers until immediately before administration.
  • Anticipate combination with a diuretic if target BP values are not reached.
  • Do not administer to patients with intravascular volume depletion until the condition has been corrected.
  • Administer with caution and under close medical supervision to patients with biliary obstructive disorders or hepatic insufficiency.
  • Do not administer to pregnant women.

 

 Assessment/Interventions

  • Obtain patient history and drug history including allergies.
  • Monitor patient for potential adverse effects and drug interactions.
  • Monitor BP and pulse. Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify health care provider.
  • Closely monitor patients on dialysis for orthostatic hypotension.
  • Monitor BP, especially patients on dialysis.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.
OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, dizziness, tachycardia, bradycardia

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that telmisartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better. Instruct patient not to increase or decrease the dosage.
  • Instruct family and patient in BP and pulse measurement skills. Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of use of this product prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning to become pregnant, or breastfeeding. Inform the patient of potential harm to the fetus.

Drug Dose ::

(tell-mih-SAHR-tan)
Micardis
Tablets: 40 mg
Tablets: 80 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 20 to 80 mg/day; usual starting dose 40 mg/day.

 

 Interactions

Digoxin: May increase plasma levels of digoxin, that may increase toxicity.

Lithium: Plasma concentrations may be increased by telmisartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

EENT: Sinusitis; pharyngitis. GI: Diarrhea. RESPIRATORY: Upper respiratory tract infection. OTHER: Back pain.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimester). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hepatic function impairment: Use with caution.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature.
  • Do not remove tablets from their blisters or containers until immediately before administration.
  • Anticipate combination with a diuretic if target BP values are not reached.
  • Do not administer to patients with intravascular volume depletion until the condition has been corrected.
  • Administer with caution and under close medical supervision to patients with biliary obstructive disorders or hepatic insufficiency.
  • Do not administer to pregnant women.

 

 Assessment/Interventions

  • Obtain patient history and drug history including allergies.
  • Monitor patient for potential adverse effects and drug interactions.
  • Monitor BP and pulse. Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify health care provider.
  • Closely monitor patients on dialysis for orthostatic hypotension.
  • Monitor BP, especially patients on dialysis.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.
OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, dizziness, tachycardia, bradycardia

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that telmisartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better. Instruct patient not to increase or decrease the dosage.
  • Instruct family and patient in BP and pulse measurement skills. Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of use of this product prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning to become pregnant, or breastfeeding. Inform the patient of potential harm to the fetus.

Contraindication ::

(tell-mih-SAHR-tan)
Micardis
Tablets: 40 mg
Tablets: 80 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 20 to 80 mg/day; usual starting dose 40 mg/day.

 

 Interactions

Digoxin: May increase plasma levels of digoxin, that may increase toxicity.

Lithium: Plasma concentrations may be increased by telmisartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

EENT: Sinusitis; pharyngitis. GI: Diarrhea. RESPIRATORY: Upper respiratory tract infection. OTHER: Back pain.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimester). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hepatic function impairment: Use with caution.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature.
  • Do not remove tablets from their blisters or containers until immediately before administration.
  • Anticipate combination with a diuretic if target BP values are not reached.
  • Do not administer to patients with intravascular volume depletion until the condition has been corrected.
  • Administer with caution and under close medical supervision to patients with biliary obstructive disorders or hepatic insufficiency.
  • Do not administer to pregnant women.

 

 Assessment/Interventions

  • Obtain patient history and drug history including allergies.
  • Monitor patient for potential adverse effects and drug interactions.
  • Monitor BP and pulse. Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify health care provider.
  • Closely monitor patients on dialysis for orthostatic hypotension.
  • Monitor BP, especially patients on dialysis.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.
OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, dizziness, tachycardia, bradycardia

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that telmisartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better. Instruct patient not to increase or decrease the dosage.
  • Instruct family and patient in BP and pulse measurement skills. Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of use of this product prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning to become pregnant, or breastfeeding. Inform the patient of potential harm to the fetus.

Drug Precautions ::

(tell-mih-SAHR-tan)
Micardis
Tablets: 40 mg
Tablets: 80 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 20 to 80 mg/day; usual starting dose 40 mg/day.

 

 Interactions

Digoxin: May increase plasma levels of digoxin, that may increase toxicity.

Lithium: Plasma concentrations may be increased by telmisartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

EENT: Sinusitis; pharyngitis. GI: Diarrhea. RESPIRATORY: Upper respiratory tract infection. OTHER: Back pain.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimester). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hepatic function impairment: Use with caution.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature.
  • Do not remove tablets from their blisters or containers until immediately before administration.
  • Anticipate combination with a diuretic if target BP values are not reached.
  • Do not administer to patients with intravascular volume depletion until the condition has been corrected.
  • Administer with caution and under close medical supervision to patients with biliary obstructive disorders or hepatic insufficiency.
  • Do not administer to pregnant women.

 

 Assessment/Interventions

  • Obtain patient history and drug history including allergies.
  • Monitor patient for potential adverse effects and drug interactions.
  • Monitor BP and pulse. Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify health care provider.
  • Closely monitor patients on dialysis for orthostatic hypotension.
  • Monitor BP, especially patients on dialysis.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.
OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, dizziness, tachycardia, bradycardia

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that telmisartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better. Instruct patient not to increase or decrease the dosage.
  • Instruct family and patient in BP and pulse measurement skills. Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of use of this product prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning to become pregnant, or breastfeeding. Inform the patient of potential harm to the fetus.

Drug Side Effects ::

(tell-mih-SAHR-tan)
Micardis
Tablets: 40 mg
Tablets: 80 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 20 to 80 mg/day; usual starting dose 40 mg/day.

 

 Interactions

Digoxin: May increase plasma levels of digoxin, that may increase toxicity.

Lithium: Plasma concentrations may be increased by telmisartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

EENT: Sinusitis; pharyngitis. GI: Diarrhea. RESPIRATORY: Upper respiratory tract infection. OTHER: Back pain.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimester). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hepatic function impairment: Use with caution.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature.
  • Do not remove tablets from their blisters or containers until immediately before administration.
  • Anticipate combination with a diuretic if target BP values are not reached.
  • Do not administer to patients with intravascular volume depletion until the condition has been corrected.
  • Administer with caution and under close medical supervision to patients with biliary obstructive disorders or hepatic insufficiency.
  • Do not administer to pregnant women.

 

 Assessment/Interventions

  • Obtain patient history and drug history including allergies.
  • Monitor patient for potential adverse effects and drug interactions.
  • Monitor BP and pulse. Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify health care provider.
  • Closely monitor patients on dialysis for orthostatic hypotension.
  • Monitor BP, especially patients on dialysis.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.
OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, dizziness, tachycardia, bradycardia

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that telmisartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better. Instruct patient not to increase or decrease the dosage.
  • Instruct family and patient in BP and pulse measurement skills. Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of use of this product prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning to become pregnant, or breastfeeding. Inform the patient of potential harm to the fetus.

Drug Mode of Action ::  

(tell-mih-SAHR-tan)
Micardis
Tablets: 40 mg
Tablets: 80 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 20 to 80 mg/day; usual starting dose 40 mg/day.

 

 Interactions

Digoxin: May increase plasma levels of digoxin, that may increase toxicity.

Lithium: Plasma concentrations may be increased by telmisartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

EENT: Sinusitis; pharyngitis. GI: Diarrhea. RESPIRATORY: Upper respiratory tract infection. OTHER: Back pain.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimester). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hepatic function impairment: Use with caution.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature.
  • Do not remove tablets from their blisters or containers until immediately before administration.
  • Anticipate combination with a diuretic if target BP values are not reached.
  • Do not administer to patients with intravascular volume depletion until the condition has been corrected.
  • Administer with caution and under close medical supervision to patients with biliary obstructive disorders or hepatic insufficiency.
  • Do not administer to pregnant women.

 

 Assessment/Interventions

  • Obtain patient history and drug history including allergies.
  • Monitor patient for potential adverse effects and drug interactions.
  • Monitor BP and pulse. Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify health care provider.
  • Closely monitor patients on dialysis for orthostatic hypotension.
  • Monitor BP, especially patients on dialysis.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.
OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, dizziness, tachycardia, bradycardia

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that telmisartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better. Instruct patient not to increase or decrease the dosage.
  • Instruct family and patient in BP and pulse measurement skills. Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of use of this product prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning to become pregnant, or breastfeeding. Inform the patient of potential harm to the fetus.

Drug Interactions ::

(tell-mih-SAHR-tan)
Micardis
Tablets: 40 mg
Tablets: 80 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 20 to 80 mg/day; usual starting dose 40 mg/day.

 

 Interactions

Digoxin: May increase plasma levels of digoxin, that may increase toxicity.

Lithium: Plasma concentrations may be increased by telmisartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

Drug Assesment ::

(tell-mih-SAHR-tan)
Micardis
Tablets: 40 mg
Tablets: 80 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 20 to 80 mg/day; usual starting dose 40 mg/day.

 

 Interactions

Digoxin: May increase plasma levels of digoxin, that may increase toxicity.

Lithium: Plasma concentrations may be increased by telmisartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

EENT: Sinusitis; pharyngitis. GI: Diarrhea. RESPIRATORY: Upper respiratory tract infection. OTHER: Back pain.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimester). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hepatic function impairment: Use with caution.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature.
  • Do not remove tablets from their blisters or containers until immediately before administration.
  • Anticipate combination with a diuretic if target BP values are not reached.
  • Do not administer to patients with intravascular volume depletion until the condition has been corrected.
  • Administer with caution and under close medical supervision to patients with biliary obstructive disorders or hepatic insufficiency.
  • Do not administer to pregnant women.

 

 Assessment/Interventions

  • Obtain patient history and drug history including allergies.
  • Monitor patient for potential adverse effects and drug interactions.
  • Monitor BP and pulse. Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify health care provider.
  • Closely monitor patients on dialysis for orthostatic hypotension.
  • Monitor BP, especially patients on dialysis.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.
OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, dizziness, tachycardia, bradycardia

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that telmisartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better. Instruct patient not to increase or decrease the dosage.
  • Instruct family and patient in BP and pulse measurement skills. Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of use of this product prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning to become pregnant, or breastfeeding. Inform the patient of potential harm to the fetus.

Drug Storage/Management ::

(tell-mih-SAHR-tan)
Micardis
Tablets: 40 mg
Tablets: 80 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 20 to 80 mg/day; usual starting dose 40 mg/day.

 

 Interactions

Digoxin: May increase plasma levels of digoxin, that may increase toxicity.

Lithium: Plasma concentrations may be increased by telmisartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

EENT: Sinusitis; pharyngitis. GI: Diarrhea. RESPIRATORY: Upper respiratory tract infection. OTHER: Back pain.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimester). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hepatic function impairment: Use with caution.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature.
  • Do not remove tablets from their blisters or containers until immediately before administration.
  • Anticipate combination with a diuretic if target BP values are not reached.
  • Do not administer to patients with intravascular volume depletion until the condition has been corrected.
  • Administer with caution and under close medical supervision to patients with biliary obstructive disorders or hepatic insufficiency.
  • Do not administer to pregnant women.

 

 Assessment/Interventions

  • Obtain patient history and drug history including allergies.
  • Monitor patient for potential adverse effects and drug interactions.
  • Monitor BP and pulse. Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify health care provider.
  • Closely monitor patients on dialysis for orthostatic hypotension.
  • Monitor BP, especially patients on dialysis.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.
OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, dizziness, tachycardia, bradycardia

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that telmisartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better. Instruct patient not to increase or decrease the dosage.
  • Instruct family and patient in BP and pulse measurement skills. Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of use of this product prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning to become pregnant, or breastfeeding. Inform the patient of potential harm to the fetus.

Drug Notes ::

(tell-mih-SAHR-tan)
Micardis
Tablets: 40 mg
Tablets: 80 mg
Class: Antihypertensive, Angiotensin II antagonist

 

 Action Antagonizes the effect of angiotensin II (vasoconstriction and aldosterone secretion) by blocking the angiotensin II (AT1 receptor) in vascular smooth muscle and the adrenal gland, producing decreased BP.

 

 Indications Treatment of hypertension.

 

 Contraindications Standard considerations.

 

 Route/Dosage

Adults: PO 20 to 80 mg/day; usual starting dose 40 mg/day.

 

 Interactions

Digoxin: May increase plasma levels of digoxin, that may increase toxicity.

Lithium: Plasma concentrations may be increased by telmisartan, resulting in an increase in the pharmacologic and adverse effects of lithium.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

EENT: Sinusitis; pharyngitis. GI: Diarrhea. RESPIRATORY: Upper respiratory tract infection. OTHER: Back pain.

 

 Precautions

Pregnancy: Category C (first trimester); category D (second and third trimester). Can cause injury or death to the fetus if used during second or third trimester. Lactation: Undetermined. CHILDREN: Safety and efficacy not established. Renal function impairment: Use with caution in patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe CHF); use may be associated with oliguria, progressive azotemia, acute renal failure, and death. Hepatic function impairment: Use with caution.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • Store at room temperature.
  • Do not remove tablets from their blisters or containers until immediately before administration.
  • Anticipate combination with a diuretic if target BP values are not reached.
  • Do not administer to patients with intravascular volume depletion until the condition has been corrected.
  • Administer with caution and under close medical supervision to patients with biliary obstructive disorders or hepatic insufficiency.
  • Do not administer to pregnant women.

 

 Assessment/Interventions

  • Obtain patient history and drug history including allergies.
  • Monitor patient for potential adverse effects and drug interactions.
  • Monitor BP and pulse. Should hypotension, tachycardia, or bradycardia occur, withhold the medication and notify health care provider.
  • Closely monitor patients on dialysis for orthostatic hypotension.
  • Monitor BP, especially patients on dialysis.
  • Monitor patient for signs of hypersensitivity including angioedema involving swelling of the face, lips, and tongue, or difficulty breathing.
OVERDOSAGE: SIGNS & SYMPTOMS
  Hypotension, dizziness, tachycardia, bradycardia

 

 Patient/Family Education

  • Instruct patient to take the medication as prescribed at the same time each day.
  • Inform patient that telmisartan controls but does not cure hypertension.
  • Caution patient to take the dose exactly as prescribed and not to stop taking the medication even if feeling better. Instruct patient not to increase or decrease the dosage.
  • Instruct family and patient in BP and pulse measurement skills. Caution patient to call primary health care provider should abnormal measurements occur.
  • Instruct patient in methods of fall prevention including rising slowly and sitting on the side of the bed before standing, especially early in therapy.
  • Inform patient of the importance of adjunct therapies such as dietary planning, regular exercise program, weight reduction, low sodium diet, alcohol reduction, smoking cessation, and stress management.
  • Instruct patient to report symptoms of weakness, fatigue, dizziness, or lightheadedness to health care provider.
  • Caution patient to notify health care provider or dentist of use of this product prior to surgery or treatment.
  • Advise women to contact health care provider if pregnant, planning to become pregnant, or breastfeeding. Inform the patient of potential harm to the fetus.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

We would like to keep you updated with special notifications.